Functional Dyspepsia
This chapter provides definition of functional dyspepsia (FD), evaluation, and diagnostic tests, methodology of clinical treatment trials with a focus on outcome measures used to determine the efficacy of treatments, and treatments including antacids, H 2 ‐receptor antagonists (H 2 ‐RAs), proton pum...
Gespeichert in:
1. Verfasser: | |
---|---|
Format: | Buchkapitel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 138 |
---|---|
container_issue | |
container_start_page | 127 |
container_title | |
container_volume | |
creator | Zanten, Sander Veldhuyzen |
description | This chapter provides definition of functional dyspepsia (FD), evaluation, and diagnostic tests, methodology of clinical treatment trials with a focus on outcome measures used to determine the efficacy of treatments, and treatments including antacids, H
2
‐receptor antagonists (H
2
‐RAs), proton pump inhibitors (PPIs), prokinetic agents, anti‐Helicobacter therapy, antidepressant therapy, and psychological interventions. A problem in every day management of FD is that primary care physicians do not readily make a distinction between gastroesophageal reflux disease (GERD) and dyspepsia, as in both instances the most likely pharmacological therapy is to prescribe a PPI. Dividing FD into subgroups has become popular despite evidence of the existence of considerable overlap among them. The ROME II classification recognized four subgroups: ulcer‐like dyspepsia, reflux‐like dyspepsia, dysmotility‐like dyspepsia, and unclassified dyspepsia. The chapter summarizes the suggested treatment algorithm for FD. The evidence for use of tricyclic antidepressants, especially amitriptyline, is getting stronger and this also true for cognitive behavioral therapy. |
doi_str_mv | 10.1002/9781119211419.ch8 |
format | Book Chapter |
fullrecord | <record><control><sourceid>wiley</sourceid><recordid>TN_cdi_wiley_ebooks_10_1002_9781119211419_ch8_ch8</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10.1002/9781119211419.ch8</sourcerecordid><originalsourceid>FETCH-LOGICAL-s150f-bfdd66d7150002e18bd95fe44a8cdc21ccc1b03a398bf332ca84644d02974f7f3</originalsourceid><addsrcrecordid>eNptkE9LAzEQxSNSUGtvXrz5BbbOJOlOcpTaVqHQSz2H_KWrS3chitRPbxalUPEwDG94vwdvGLtFmCIAv9ekEFFzRIl66nfqjF0dD3R-FELRBZvk_AqFQiAifclulh97_950e9vePR5yH_vc2Gs2SrbNcfK7x-xludjOn6r1ZvU8f1hXGWeQKpdCqOtARZTEiMoFPUtRSqt88By99-hAWKGVS0Jwb5WspQzANclESYxZ9ZP72bTxYKLrurdsTvqYr6Y3pZPpw-DHf_wIZvjDH25gyohvYpFObQ</addsrcrecordid><sourcetype>Enrichment Source</sourcetype><iscdi>true</iscdi><recordtype>book_chapter</recordtype></control><display><type>book_chapter</type><title>Functional Dyspepsia</title><source>eBooks on EBSCOhost</source><creator>Zanten, Sander Veldhuyzen</creator><contributor>Feagan, Brian G ; McDonald, John W D ; Kahrilas, Peter J ; Jalan, Rajiv</contributor><creatorcontrib>Zanten, Sander Veldhuyzen ; Feagan, Brian G ; McDonald, John W D ; Kahrilas, Peter J ; Jalan, Rajiv</creatorcontrib><description>This chapter provides definition of functional dyspepsia (FD), evaluation, and diagnostic tests, methodology of clinical treatment trials with a focus on outcome measures used to determine the efficacy of treatments, and treatments including antacids, H
2
‐receptor antagonists (H
2
‐RAs), proton pump inhibitors (PPIs), prokinetic agents, anti‐Helicobacter therapy, antidepressant therapy, and psychological interventions. A problem in every day management of FD is that primary care physicians do not readily make a distinction between gastroesophageal reflux disease (GERD) and dyspepsia, as in both instances the most likely pharmacological therapy is to prescribe a PPI. Dividing FD into subgroups has become popular despite evidence of the existence of considerable overlap among them. The ROME II classification recognized four subgroups: ulcer‐like dyspepsia, reflux‐like dyspepsia, dysmotility‐like dyspepsia, and unclassified dyspepsia. The chapter summarizes the suggested treatment algorithm for FD. The evidence for use of tricyclic antidepressants, especially amitriptyline, is getting stronger and this also true for cognitive behavioral therapy.</description><identifier>ISBN: 1119211387</identifier><identifier>ISBN: 9781119211389</identifier><identifier>EISBN: 1119211417</identifier><identifier>EISBN: 9781119211419</identifier><identifier>DOI: 10.1002/9781119211419.ch8</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>anti‐Helicobacter therapy ; cognitive behavioral therapy ; functional dyspepsia ; gastroesophageal reflux disease ; prokinetic agents ; proton pump inhibitors ; ROME II classification ; tricyclic antidepressants</subject><ispartof>Evidence‐based Gastroenterology and Hepatology 4e, 2019, p.127-138</ispartof><rights>Copyright © 2019 John Wiley & Sons, Ltd. All rights reserved.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>775,776,780,789,27902</link.rule.ids></links><search><contributor>Feagan, Brian G</contributor><contributor>McDonald, John W D</contributor><contributor>Kahrilas, Peter J</contributor><contributor>Jalan, Rajiv</contributor><creatorcontrib>Zanten, Sander Veldhuyzen</creatorcontrib><title>Functional Dyspepsia</title><title>Evidence‐based Gastroenterology and Hepatology 4e</title><description>This chapter provides definition of functional dyspepsia (FD), evaluation, and diagnostic tests, methodology of clinical treatment trials with a focus on outcome measures used to determine the efficacy of treatments, and treatments including antacids, H
2
‐receptor antagonists (H
2
‐RAs), proton pump inhibitors (PPIs), prokinetic agents, anti‐Helicobacter therapy, antidepressant therapy, and psychological interventions. A problem in every day management of FD is that primary care physicians do not readily make a distinction between gastroesophageal reflux disease (GERD) and dyspepsia, as in both instances the most likely pharmacological therapy is to prescribe a PPI. Dividing FD into subgroups has become popular despite evidence of the existence of considerable overlap among them. The ROME II classification recognized four subgroups: ulcer‐like dyspepsia, reflux‐like dyspepsia, dysmotility‐like dyspepsia, and unclassified dyspepsia. The chapter summarizes the suggested treatment algorithm for FD. The evidence for use of tricyclic antidepressants, especially amitriptyline, is getting stronger and this also true for cognitive behavioral therapy.</description><subject>anti‐Helicobacter therapy</subject><subject>cognitive behavioral therapy</subject><subject>functional dyspepsia</subject><subject>gastroesophageal reflux disease</subject><subject>prokinetic agents</subject><subject>proton pump inhibitors</subject><subject>ROME II classification</subject><subject>tricyclic antidepressants</subject><isbn>1119211387</isbn><isbn>9781119211389</isbn><isbn>1119211417</isbn><isbn>9781119211419</isbn><fulltext>true</fulltext><rsrctype>book_chapter</rsrctype><creationdate>2019</creationdate><recordtype>book_chapter</recordtype><sourceid/><recordid>eNptkE9LAzEQxSNSUGtvXrz5BbbOJOlOcpTaVqHQSz2H_KWrS3chitRPbxalUPEwDG94vwdvGLtFmCIAv9ekEFFzRIl66nfqjF0dD3R-FELRBZvk_AqFQiAifclulh97_950e9vePR5yH_vc2Gs2SrbNcfK7x-xludjOn6r1ZvU8f1hXGWeQKpdCqOtARZTEiMoFPUtRSqt88By99-hAWKGVS0Jwb5WspQzANclESYxZ9ZP72bTxYKLrurdsTvqYr6Y3pZPpw-DHf_wIZvjDH25gyohvYpFObQ</recordid><startdate>20190423</startdate><enddate>20190423</enddate><creator>Zanten, Sander Veldhuyzen</creator><general>John Wiley & Sons, Ltd</general><scope/></search><sort><creationdate>20190423</creationdate><title>Functional Dyspepsia</title><author>Zanten, Sander Veldhuyzen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-s150f-bfdd66d7150002e18bd95fe44a8cdc21ccc1b03a398bf332ca84644d02974f7f3</frbrgroupid><rsrctype>book_chapters</rsrctype><prefilter>book_chapters</prefilter><language>eng</language><creationdate>2019</creationdate><topic>anti‐Helicobacter therapy</topic><topic>cognitive behavioral therapy</topic><topic>functional dyspepsia</topic><topic>gastroesophageal reflux disease</topic><topic>prokinetic agents</topic><topic>proton pump inhibitors</topic><topic>ROME II classification</topic><topic>tricyclic antidepressants</topic><toplevel>online_resources</toplevel><creatorcontrib>Zanten, Sander Veldhuyzen</creatorcontrib></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zanten, Sander Veldhuyzen</au><au>Feagan, Brian G</au><au>McDonald, John W D</au><au>Kahrilas, Peter J</au><au>Jalan, Rajiv</au><format>book</format><genre>bookitem</genre><ristype>CHAP</ristype><atitle>Functional Dyspepsia</atitle><btitle>Evidence‐based Gastroenterology and Hepatology 4e</btitle><date>2019-04-23</date><risdate>2019</risdate><spage>127</spage><epage>138</epage><pages>127-138</pages><isbn>1119211387</isbn><isbn>9781119211389</isbn><eisbn>1119211417</eisbn><eisbn>9781119211419</eisbn><abstract>This chapter provides definition of functional dyspepsia (FD), evaluation, and diagnostic tests, methodology of clinical treatment trials with a focus on outcome measures used to determine the efficacy of treatments, and treatments including antacids, H
2
‐receptor antagonists (H
2
‐RAs), proton pump inhibitors (PPIs), prokinetic agents, anti‐Helicobacter therapy, antidepressant therapy, and psychological interventions. A problem in every day management of FD is that primary care physicians do not readily make a distinction between gastroesophageal reflux disease (GERD) and dyspepsia, as in both instances the most likely pharmacological therapy is to prescribe a PPI. Dividing FD into subgroups has become popular despite evidence of the existence of considerable overlap among them. The ROME II classification recognized four subgroups: ulcer‐like dyspepsia, reflux‐like dyspepsia, dysmotility‐like dyspepsia, and unclassified dyspepsia. The chapter summarizes the suggested treatment algorithm for FD. The evidence for use of tricyclic antidepressants, especially amitriptyline, is getting stronger and this also true for cognitive behavioral therapy.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><doi>10.1002/9781119211419.ch8</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISBN: 1119211387 |
ispartof | Evidence‐based Gastroenterology and Hepatology 4e, 2019, p.127-138 |
issn | |
language | eng |
recordid | cdi_wiley_ebooks_10_1002_9781119211419_ch8_ch8 |
source | eBooks on EBSCOhost |
subjects | anti‐Helicobacter therapy cognitive behavioral therapy functional dyspepsia gastroesophageal reflux disease prokinetic agents proton pump inhibitors ROME II classification tricyclic antidepressants |
title | Functional Dyspepsia |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T23%3A59%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=bookitem&rft.atitle=Functional%20Dyspepsia&rft.btitle=Evidence%E2%80%90based%20Gastroenterology%20and%20Hepatology%204e&rft.au=Zanten,%20Sander%20Veldhuyzen&rft.date=2019-04-23&rft.spage=127&rft.epage=138&rft.pages=127-138&rft.isbn=1119211387&rft.isbn_list=9781119211389&rft_id=info:doi/10.1002/9781119211419.ch8&rft_dat=%3Cwiley%3E10.1002/9781119211419.ch8%3C/wiley%3E%3Curl%3E%3C/url%3E&rft.eisbn=1119211417&rft.eisbn_list=9781119211419&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |